We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Atyr Pharma (ATYR - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Atyr Pharma is a member of the Medical sector. This group includes 1012 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Atyr Pharma is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ATYR's full-year earnings has moved 19.4% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ATYR has returned 6.9% so far this year. Meanwhile, the Medical sector has returned an average of 4.8% on a year-to-date basis. This means that Atyr Pharma is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Delcath Systems, Inc. (DCTH - Free Report) . The stock is up 11.6% year-to-date.
Over the past three months, Delcath Systems, Inc.'s consensus EPS estimate for the current year has increased 132.9%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Atyr Pharma belongs to the Medical - Biomedical and Genetics industry, a group that includes 510 individual stocks and currently sits at #73 in the Zacks Industry Rank. On average, this group has gained an average of 6.3% so far this year, meaning that ATYR is performing better in terms of year-to-date returns.
On the other hand, Delcath Systems, Inc. belongs to the Medical - Instruments industry. This 84-stock industry is currently ranked #129. The industry has moved -3.5% year to date.
Investors with an interest in Medical stocks should continue to track Atyr Pharma and Delcath Systems, Inc. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Atyr Pharma (ATYR - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Atyr Pharma is a member of the Medical sector. This group includes 1012 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Atyr Pharma is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ATYR's full-year earnings has moved 19.4% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ATYR has returned 6.9% so far this year. Meanwhile, the Medical sector has returned an average of 4.8% on a year-to-date basis. This means that Atyr Pharma is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Delcath Systems, Inc. (DCTH - Free Report) . The stock is up 11.6% year-to-date.
Over the past three months, Delcath Systems, Inc.'s consensus EPS estimate for the current year has increased 132.9%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Atyr Pharma belongs to the Medical - Biomedical and Genetics industry, a group that includes 510 individual stocks and currently sits at #73 in the Zacks Industry Rank. On average, this group has gained an average of 6.3% so far this year, meaning that ATYR is performing better in terms of year-to-date returns.
On the other hand, Delcath Systems, Inc. belongs to the Medical - Instruments industry. This 84-stock industry is currently ranked #129. The industry has moved -3.5% year to date.
Investors with an interest in Medical stocks should continue to track Atyr Pharma and Delcath Systems, Inc. These stocks will be looking to continue their solid performance.